
Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Pepaxti
(melphalan flufenamide)
Uses, side effects, dosage information & price range
About this medicine
Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4).
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
melphalan flufenamide
Category
Antineoplastic agents
Manufacturer
Oncopeptides AB (publ)
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.